Asker Healthcare Group AB

Asker Healthcare Group AB

6.46
EUR
+0.13
(+1.97%)
0.16EPS
44.92P/E
2.72BMarket Cap
Nov 04Next Earn
Asker Healthcare Group AB
GETTEX:I88
(Gettex)

Recent

price

6.46

P/E

ratio

44.92

div

yld

0.54%

ROIC.AI

2022
2023
2024
2025
TTM
SEK
30.59
35.12
39.23
43.83
46.65
Revenue per Share
1.12
0.53
0.94
1.28
1.75
Basic EPS, GAAP
2.23
2.35
2.29
1.93
1.69
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.39
Dividend per Share
7.21
7.89
9.06
17.11
18.22
Book Value per Share
-8.17
-8.52
-9.36
-7.41
-7.97
Tangible Book Value per Share
383
383
383
383
383
Basic Weighted Avg Shares
11,718
13,453
15,025
16,787
17,870
Sales/Revenue/Turnover
6.2
4.34
6.47
5.95
6.65
Operating Margin (%)
395
548
608
816
- -
Depreciation Expense
430
203
360
492
671
Net Income, GAAP
22.64
33.44
32.74
22.61
21.92
Effective Tax Rate (%)
3.67
1.51
2.4
2.93
3.75
Profit Margin (%)
1,175
1,132
1,285
1,435
1,355
Working Capital
4,477
4,552
5,346
4,951
4,984
LT Debt
2,791
3,041
3,502
6,588
7,019
Total Equity
- -
4.91
7.35
7.09
7.75
Return on Invested Capital (%)
- -
4.85
6.27
5.83
8.47
Return on Capital (%)
- -
7.02
11.09
9.82
10.18
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
863
1,010
1,492
LT Borrowings
4,224
4,242
4,256
LT Finance Leases
727
766
728
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
383
383
383
Market Capitalization
32,312
26,256
30,144

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,472
5,853
5,794
Cash, Cash Equivalents & STI
884
945
777
Accounts Receivable, Net
2,052
2,153
2,096
Inventories
2,041
2,183
2,364
Total Current Liabilities
4,037
4,477
4,439
Payables & Accruals
- -
- -
- -
ST Debt
863
1,010
1,492
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
88.12%
Free Cash Flow
- -
- -
-16.04%
Net Income, GAAP
- -
- -
36.67%
Sales/Revenue/Turnover
- -
- -
11.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,455
3,669
- -
- -
15,025
2025
3,995
3,987
- -
4,676
16,787
2026
4,521
4,686
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.29
- -
0.28
0.94
2025
0.28
0.34
- -
0.34
1.28
2026
0.5
0.57
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
0.39
- -
- -
- -
Business
Asker Healthcare Group AB (ASKER.ST) is a Sweden-based healthcare company that provides medical products, devices, equipment, and related solutions to caregivers, patients, hospitals, clinics, and healthcare institutions across Europe. Founded in 2018 and headquartered in Danderyd, Sweden, the group operates through more than 50 companies in 19 countries, employing over 4,500 people and generating revenues of SEK 16 billion; it focuses on improving patient outcomes, reducing total cost of care, and ensuring a sustainable value chain via its "twin engine" strategy of organic growth and acquisitions. Core offerings encompass a broad portfolio of medical supplies, consumables, and equipment distributed by subsidiaries such as OneMed (50,000 stocked products including devices, logistics, and services like Decision Support Guide and OneWound across Nordic and Baltic markets), Bosman (stoma, wound, diabetes, and urological care devices and support in the Netherlands), QRS (medical equipment and consumables for hospitals and clinics in Netherlands and Belgium), Diashop (diabetes care products via shops and online in Germany), FysioSupplies (physiotherapy products for professionals and consumers across Europe), and Evercare Medical (comprehensive medical supplies Europe-wide); additional services include 4PL logistics via OneMed Services, aesthetic equipment via Astomed, and specialized solutions like aScan's inventory management and EvivaMed's diabetes and wound care products. Recent developments include the acquisition of Novus Med Holdings Limited in 2025, a UK distributor of endoscopic surgery technologies and patient positioning systems that enhances minimally invasive surgery offerings and bolsters UK hospital partnerships with positive EBITA impact; the purchase of Health Net Connections, a British healthcare software firm, earlier that year; the November 2025 acquisition of InnoMedicus AG, a specialist in urology devices, software, and training for prostate cancer therapies generating SEK 50 million in 2024 revenue; acquisition of distribution rights for orthopedic implants in the Baltic region; and ongoing construction of a new distribution center in Gothenburg, supporting a robust pipeline targeting 10-20 annual acquisitions amid Q2 2025 net sales growth of 9% to SEK 4 billion and EBITDA margin progress toward 10%.